Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Ensem Therapeutics, Inc.

Ensem Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of ETX-636, a Potential Best-In-Class Allosteric Pan-Mutant-Selective PI3Kα Inhibitor and Degrader
From Ensem Therapeutics, Inc.
Via Business Wire
Ensem Therapeutics Announces U.S. FDA IND Clearance to Initiate Clinical Development of ETX-636
From Ensem Therapeutics, Inc.
Via Business Wire
Ensem Therapeutics Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference
From Ensem Therapeutics, Inc.
Via Business Wire
Ensem Therapeutics To Present Preclinical Data for Potential Best-in-Class Oral CDK2 Inhibitor at San Antonio Breast Cancer Symposium
From Ensem Therapeutics, Inc.
Via Business Wire
Ensem Therapeutics To Present Preclinical Data for Potential Best-in-Class Allosteric Pan-Mutant-Selective PI3Kα Inhibitor and Degrader at San Antonio Breast Cancer Symposium
From Ensem Therapeutics, Inc.
Via Business Wire
Ensem Therapeutics Announces Achievement of Milestone Following Entry of Small Molecule CDK2 Inhibitor into Clinical Trials for Solid Tumors
From Ensem Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.